Safety cannot be decided from the words “stem cells”, “natural” or “your own cells”. It requires an assessment of the particular product, collection and administration procedures, your health and the care arrangements.
On this page
Separate the sources of risk
| Part of treatment | What to clarify |
|---|---|
| Collection | Whether tissue or blood collection is needed and its risks |
| Preparation | Identity, contamination testing and handling of the product |
| Administration | Risks of the proposed injection, infusion or surgery |
| Other medicines | Risks from medicines given alongside treatment |
| Follow-up | How problems are detected and managed |
What is known about unapproved products?
The US FDA has reported serious harms associated with unapproved regenerative products, including infection and unwanted tissue growth. Those reports are a warning about unproven products, not a numerical risk estimate for every cell medicine. US FDA: regenerative medicine patient information.
Ask for the safety data for the actual proposal, including serious events, long-term monitoring and the number of patients studied. A small study reporting no serious events cannot exclude uncommon harm.
Assess the facility and care plan
Ask who performs the procedure, who stays responsible during observation and where emergency treatment would occur. Obtain a clinical contact for complications and instructions for after you return home. Discuss the plan with the clinician who normally manages your condition.
- What would make you postpone or decline treatment?
- How are product identity and batch records documented?
- What symptoms require urgent assessment?
- Who receives and investigates adverse-event reports?
Safety is not the same as effectiveness
A treatment could produce few observed short-term problems and still offer no worthwhile benefit. Conversely, a beneficial treatment may carry important risks. Read the effectiveness guide with this page, rather than using either question alone.
Common questions
Are my own cells automatically safe?
No. Collection, preparation, handling and delivery still require assessment.
Does “no downtime” mean no risk?
No. It is a claim about the anticipated schedule, not a complete safety assessment. For possible symptoms and reporting questions, see side effects.
Ask about an assessment
For questions about the review process, availability or a written estimate, message Thailand Stem Cell Clinic. Ask how to share records securely. An enquiry does not confirm eligibility or that a particular treatment is offered.
All FAQs · Treatment guides · Contact information
Sources and further reading
General information, not an individual medical recommendation. Prices, coverage, eligibility and authorisation require case-specific confirmation. Source links describe their own research and jurisdictions.